Literature DB >> 18070184

Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.

J Suárez1, R Vera, E Balén, M Gómez, F Arias, J M Lera, J Herrera, C Zazpe.   

Abstract

OBJECTIVE: The reduction in tumour stage induced by full course radiotherapy plus chemotherapy is apparent from histological changes. The purpose of this study was to determine the rate of complete pathological response and to evaluate the prognostic value for disease free survival (DFS) and disease specific survival (DSS) of the response. The relation between pretreatment variables (age, gender, stage, tumour height and [carcinoembryogenic antigen (CEA)] and postsurgical variables was compared to the pathological response.
METHOD: A total of 119 patients with stage II or III rectal cancer underwent surgery 6 weeks after neoadjuvant treatment. Group A included patients with a complete or good pathological response (Mandard grade I-II) and group B patients with a poor response (Mandard grade III-IV-V). The pretreatment endo-rectal ultrasound scan stage was compared with histopathology stage of the resected specimen. DFS and DSS were compared using the log-rank test.
RESULTS: All 119 patients (mean age 67.9 years, 83 males) underwent resection. The tumour was located in the upper, middle and lower third of the rectum in 11, 51 and 57 patients. 88 patients had a low anterior resection, 28 patients abdomino-perineal resection and three a Hartmann's operation. There was no postoperative death. The circumferential margin (CM) was involved in 10%. A complete pathological response was observed in 17 (14.2%) patients. Thirty-six (30.2%) patients had a group A and 83 a group B response. Group A showed DFS to be significantly higher than group B (log rank: P = 0.007). The DSS rate was not significantly different between the two groups (log rank P = 0.113). Down-staging was not related with DFS. No relation was found between pretreatment variables and response. A good pathological response was related to a lower rate of permanent colostomy but not with CM involvement or the number of lymph nodes.
CONCLUSION: Tumour regression of grades I or II was a good indicator of DFS in locally advanced rectal cancer, treated by neoadjuvant chemotherapy and radiotherapy. Patients with a high regression grade were associated with a lower incidence of definitive stoma formation. The regression grade was shown to be a better prognostic factor than down-staging.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070184     DOI: 10.1111/j.1463-1318.2007.01424.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  42 in total

1.  Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Robert Farkas; Eva Pozsgai; Andrew V Schally; Andras Szigeti; Edit Szigeti; Zoltan Laszlo; Andras Papp; Eva Gomori; Laszlo Mangel; Peter O Horvath; Szabolcs Bellyei
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-08       Impact factor: 4.553

2.  Invited commentary on "Yun HR, Kim HC, Kim SH et al. (2010) Cytokeratin staining for complete remission in rectal cancer after chemoradiation. Int J Colorect Dis.

Authors:  Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2010-06-09       Impact factor: 2.571

3.  Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Marianne Huebner; Bruce G Wolff; Thomas C Smyrk; Jeremiah Aakre; David W Larson
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

Review 4.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

5.  DNA content analysis of colorectal cancer defines a distinct 'microsatellite and chromosome stable' group but does not predict response to radiotherapy.

Authors:  Wakkas Fadhil; Karin Kindle; Darryl Jackson; Abed Zaitoun; Nina Lane; Adrian Robins; Mohammad Ilyas
Journal:  Int J Exp Pathol       Date:  2014-02       Impact factor: 1.925

6.  In rectal cancer, the type of desmoplastic response after preoperative chemoradiotherapy is associated with prognosis.

Authors:  Hideki Ueno; Eiji Shinto; Yojiro Hashiguchi; Hideyuki Shimazaki; Yoshiki Kajiwara; Takahiro Sueyama; Junji Yamamoto; Kazuo Hase
Journal:  Virchows Arch       Date:  2015-03-29       Impact factor: 4.064

7.  Response to chemoradiotherapy and lymph node involvement in locally advanced rectal cancer.

Authors:  Luis J García-Flórez; Guillermo Gómez-Álvarez; Ana M Frunza; Luis Barneo-Serra; Manuel F Fresno-Forcelledo
Journal:  World J Gastrointest Surg       Date:  2015-09-27

8.  Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer.

Authors:  Byoung Yong Shim; Ji-Han Jung; Kang-Moon Lee; Hyung-Jin Kim; Sook Hee Hong; Sung Hwan Kim; Der Sheng Sun; Hyeon-Min Cho
Journal:  Int J Colorectal Dis       Date:  2012-07-31       Impact factor: 2.571

9.  Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy.

Authors:  Young Joo Park; Byung Ryul Oh; Sang Woo Lim; Jung Wook Huh; Jae Kyun Joo; Young Jin Kim; Hyeong Rok Kim
Journal:  J Korean Soc Coloproctol       Date:  2010-08-31

10.  Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study.

Authors:  Mi Joo Chung; Taek Keun Nam; Jae Uk Jeong; Sung Hwan Kim; Kyubo Kim; Hong Seok Jang; Bae Kwon Jeong; Jong Hoon Lee
Journal:  Int J Colorectal Dis       Date:  2016-07-28       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.